Actively hiring
Oncology Therapeutics
Health Care
Genomics & Genetic Testing
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
2
Y Combinator, Union Square Ventures
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Similar startupsby what they do, their industry and backers

ゲノム ( DNA )、エピゲノム、トランスクリプトーム ( RNA )を独自の技術で解析し、研究開発の効率・精度を格段に向上させます。次世代シーケンス( NGS )/ エピジェネティクス 研究の 実験デザイン から 情報 解析、論文化、事業化までオーダーメイドで支援します。.

Yemaachi is creating the world's most diverse cancer bio-database to develop the next generation of cancer drugs that are effective in…

What if we made as many cancer drugs next year as we have in the last decade?

Innovating life-changing medicines for cancer patients. At Kumquat, we're on a mission to transform cancer treatment by delivering durable…

Targeting the Tumor Ecosystem to address cancer drug resistance and improve patients’ lives.

Advancing precision neurology through brain-derived circular RNA, blood-based biomarkers, and molecular intelligence for neuroscience…
News
Genezen Announces Manufacturing Partnership with Humane Genomics to Advance Oncolytic Virus Therapy for Pediatric Liver Cancer
Genezen, a leading viral vector Contract Development and Manufacturing Organization (CDMO), and Humane Genomics, a biotechnology company developing oncolytic viral therapies, today announced a partnership for process transfer and cGMP manufacturing of HGI
Read more
Report
Humane Genomics
John von Neumann famously postulated the idea of a Universal Constructor, a machine that could build anything, itself included. While that may forever remain elusive, our cells contain marvelous constructors called Ribosomes, which assemble all the protei
Read more
Report

Y Combinator
Union Square Ventures